PCM
EBS icon

Penserra Capital Management’s Emergent Biosolutions EBS Stock Holding History

Penserra Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-53,139
Closed -$5.49M – 1038
2020
Q3 		$5.49M Buy
+53,139
New +$5.73M 0.21% 122

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Penserra Capital Management's EBS Position: Q4 2020 in Review

Penserra Capital Management sold out of Emergent Biosolutions (EBS) in Q4 2020, closing a stake of 53,139 shares — an estimated $5.49M sold.

Penserra Capital Management first reported a position in EBS in Q3 2020 and held it in 1 quarter. The position peaked at $5.49M in Q3 2020. 353 funds tracked by Wall St. Rank hold EBS as of Q4 2020.

  • Penserra Capital Management reported no remaining Emergent Biosolutions position as of Q4 2020 after selling out during the quarter.
  • Penserra Capital Management sold 53,139 Emergent Biosolutions shares in Q4 2020, an estimated $5.49M.
  • Penserra Capital Management first reported a position in Emergent Biosolutions in Q3 2020 and held it in 1 quarter.
  • Penserra Capital Management's Emergent Biosolutions position peaked at $5.49M in Q3 2020.
  • 353 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2020.

Based on Penserra Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.